Through its existing UK licence with PGxHealth™, a division of Clinical Data, Inc. (NASDQ: CLDA), Lab21 offers exclusive U.K. and Ireland access to the Familion® portfolio of tests for Long QT and Brugada Syndromes and has now added two new assays for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Hypertrophic Cardiomyopathy (HCM) to its range of tests.
CPVT is potentially the most lethal of the inherited cardiac channelopathies, being particularly difficult to diagnose in the absence of genetic testing. HCM is the most common form of heart muscle disease, affecting 1 in 500 individuals and is the most common cause of sudden cardiac death in people below the age of 30.
Berwyn Clarke, Lab21 Chief Scientific and Development Officer commented: “We are delighted to expand our relationship with PGxHealth, who we believe is the market leader in the development of advanced genetic tests for inherited cardiac conditions. The addition of CPVT and HCM to the Familion stable substantially assists UK cardiologists in the accurate diagnosis of cardiac disease. By enabling cardiologists to quickly identify a patient’s risk, the most appropriate monitoring, treatment or lifestyle options can be implemented, significantly improving patient health.”
Lab21 Commercial Manager, Richard Hughes, added: “The addition of these two new tests provides one of the most comprehensive panels of validated cardiovascular genetic tests available in Europe. As the Familion LQTS tests have become more widely adopted, many of our customers have requested the introduction of tests for CPVT and HCM and we are delighted that through PGxHealth we are now able to offer this.”
